![]() “These developments are concerning given that the Covishield vaccine has been the backbone of the EU-supported COVAX contributions to the AU Member States’ vaccination programmes. South Africa's President Ramaphosa urges G7 nations to plug Covid-19 funding gap (Photo by Stefan Rousseau / POOL / AFP) (Photo by STEFAN ROUSSEAU/POOL/AFP via Getty Images) STEFAN ROUSSEAU/AFP/POOL/AFP via Getty Images “The current applicability guidelines put at risk the equitable treatment of persons having received their vaccines in countries profiting from the EU-supported COVAX Facility, including the majority of the African Union (AU) Member States,” the joint statement said.īritain's Prime Minister Boris Johnson (R) and South Africa's President Cyril Ramaphosa take part in a bilateral meeting at the G7 summit in Carbis bay, Cornwall on June 13, 2021. The AU and Africa CDC urged the EU Commission, in a joint statement on Monday, “to consider increasing mandatory access to those vaccines deemed suitable for global rollout through the EU-supported COVAX Facility.” The fact that two doses of the Indian-produced AstraZeneca vaccine does not guarantee travelers entry to the EU means a huge part of the world is excluded from the bloc’s current travel policy.Ĭovishield has been described as the “backbone” of COVAX contributions to low- and middle-income countries. Travelers may also enter the EU by presenting a negative PCR test. The EU told CNN in a statement Wednesday that the certificate was “not a prerequisite for travel into the European Union” and that “Member States could also allow entry for people vaccinated with vaccines having completed the WHO Emergency Use Listing process,” which includes Covishield. The EMA statement added: “Should we receive a marketing authorization application for Covishield or should any change to the approved manufacturing sites for Vaxzevria be approved, we would communicate about it.” ![]() “Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law therefore requires the manufacturing sites and production process to be assessed and approved as part of the authorization process.” ![]() ![]() “This is because vaccines are biological products,” the agency stated. Even though it may use an analogous production technology to Vaxzevria, Covishield as such is not currently approved under EU rules,” the EMA said. “In the EU, the vaccine called Covishield does not currently have a marketing authorization. AFP PHOTO / VALERY HACHE (Photo credit should read VALERY HACHE/AFP via Getty Images) VALERY HACHE/AFP via Getty ImagesĮU Digital Covid Certificate: Everything you need to know A woman swims in the mediterranean sea in the French riviera city of Beaulieu-Sur-Mer, on August 5, 2017. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |